– Enzol Injection Ranitidine is a H2 receptor antagonist used primarily for reducing gastric acid secretion.
– Each 2ml ampoule contains 50mg of ranitidine hydrochloride and is intended for use by registered medical practitioners.
– Mechanism of Action: Ranitidine inhibits both basal and stimulated gastric acid secretion, effectively reducing volume, acidity, and pepsin content.
– Absorption: Peak plasma concentration occurs within 15 minutes post-injection.
– Distribution: Low plasma protein binding (15%) with a large volume of distribution (96-142 L).
– Elimination: Terminal half-life of 2-3 hours, primarily eliminated via the kidneys.
– Indicated for treating benign gastric and duodenal ulcers, reflux oesophagitis, and stress ulcer prophylaxis in seriously ill patients.
– Also used in Zollinger-Ellison Syndrome and for gastro-oesophageal reflux in children aged 6 months to 18 years.
– Hypersensitivity to Ranitidine or any excipients .
– Ranitidine may alter the absorption and metabolism of other drugs, necessitating dosage adjustments.
– Notably affects drugs metabolized by the cytochrome P450 system and can alter gastric pH, impacting drug bioavailability.
– May mask symptoms of gastric carcinoma; malignancy should be ruled out before treatment.
– Increased risk of community-acquired pneumonia in certain populations.
– Caution in patients with renal impairment; dosage adjustments are necessary.
– Very Rare: Blood count changes, hypersensitivity reactions, mental confusion, and bradycardia.
– Common: Abdominal pain, constipation, and nausea.
– Adults: 50mg via slow IV injection or IM every 6-8 hours.
– Children: Doses adjusted based on weight, with a maximum of 50mg.
– Renal Impairment: Reduced doses recommended for patients with severe impairment .
– Ranitidine crosses the placenta; use only if essential .
– Excreted in breast milk; caution advised during nursing .
– Store below 30ºC and protect from light.